A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

This study tests a new oral drug called HJ-004-02 for people with a specific type of non-small cell lung cancer (NSCLC) that has a mutation in a gene called EGFR, to evaluate its safety, how the body processes it, and early signs of effectiveness. **You may be eligible if...** - You are 18–74 years old - You have been diagnosed with non-squamous non-small cell lung cancer - Your tumor has one or more EGFR gene mutations - Your cancer has progressed after standard treatments, or you cannot tolerate them - You are well enough to carry out daily activities (ECOG 0–1) - Your blood counts and organ function are within safe ranges - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have squamous cell lung cancer - Your cancer does not have an EGFR mutation - You have active brain metastases that require treatment - You are pregnant or breastfeeding - Your organ function (kidneys, liver, blood) does not meet minimum thresholds Talk to your doctor to see if this trial is right for you.